

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM524106

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST
<b>SEQUENCE:</b>	1

## CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
GOLDMAN SACHS SPECIALTY LENDING GROUP, L.P., as Collateral Agent		05/17/2019	Limited Partnership: DELAWARE

## RECEIVING PARTY DATA

<b>Name:</b>	CUTISPHARMA, INC.
<b>Street Address:</b>	841 Woburn Street
<b>City:</b>	Wilmington
<b>State/Country:</b>	MASSACHUSETTS
<b>Postal Code:</b>	01887
<b>Entity Type:</b>	Corporation: DELAWARE

## PROPERTY NUMBERS Total: 12

Property Type	Number	Word Mark
Registration Number:	4420640	CP
Registration Number:	4473417	CUTISPHARMA
Registration Number:	5244475	FIRST
Registration Number:	3275609	FIRST
Registration Number:	2636155	FIRST RX
Registration Number:	4678283	ORAL SOLUTION
Registration Number:	4416915	ORAL SUSPENSION
Registration Number:	4416916	SUPPOSITORY
Registration Number:	4615796	TOPICAL
Registration Number:	3410259	SMART PRODUCTS FOR SMART PEOPLE
Registration Number:	5055386	TRANSFORMING COMPOUNDING THROUGH INNOVAT
Registration Number:	5360667	TRANSFORMING MEDICINE THROUGH INNOVATION

## CORRESPONDENCE DATA

Fax Number: 4045725100

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

TRADEMARK

**Phone:** 404-572-3493  
**Email:** kosborne@kslaw.com  
**Correspondent Name:** Karen Osborne, Senior Paralegal  
**Address Line 1:** 1180 Peachtree Street N.E.  
**Address Line 2:** King & Spalding LLP  
**Address Line 4:** Atlanta, GEORGIA 30309

**ATTORNEY DOCKET NUMBER:** 14868.015097

**NAME OF SUBMITTER:** Karen Osborne

**SIGNATURE:** //Karen Osborne//

**DATE SIGNED:** 05/17/2019

**Total Attachments: 5**

source=15B- CutisPharma - Release of Security Interest in Trademarks (GS) (Executed)#page1.tif

source=15B- CutisPharma - Release of Security Interest in Trademarks (GS) (Executed)#page2.tif

source=15B- CutisPharma - Release of Security Interest in Trademarks (GS) (Executed)#page3.tif

source=15B- CutisPharma - Release of Security Interest in Trademarks (GS) (Executed)#page4.tif

source=15B- CutisPharma - Release of Security Interest in Trademarks (GS) (Executed)#page5.tif

**RELEASE OF SECURITY INTERESTS IN TRADEMARKS**

THIS RELEASE OF SECURITY INTERESTS IN TRADEMARKS (this “Release”), dated as of May 17, 2019, is executed by GOLDMAN SACHS SPECIALTY LENDING GROUP, L.P., in its capacity as Collateral Agent (in such capacity, “Collateral Agent”), in favor of CUTISPHARMA, INC., a Delaware corporation (“Grantor”). All capitalized terms used in this Release and not otherwise defined herein, shall have the respective meanings given to such terms in the Security Agreement (as defined below).

RECITALS

A. WHEREAS, Grantor has, pursuant to that certain Trademark Security Agreement dated March 21, 2018, recorded in the United States Patent and Trademark Office (the “USPTO”) on March 21, 2018 at Reel 6296, Frame 0780, (as the same may be amended, amended and restated, restated, supplemented, modified or otherwise in effect prior to the date hereof, the “Security Agreement”) granted to Collateral Agent a security interest in and to all of Grantor’s right, title and interest in and to the Trademark Collateral, including without limitation those trademarks listed on Exhibit A attached hereto (collectively, the “Released Collateral”); and

B. WHEREAS, Collateral Agent wishes to terminate and release its security interest in and to the Released Collateral as provided in this release.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Collateral Agent hereby terminates and releases, without recourse its security interest in and to the Released Collateral and terminates the Security Agreement. Collateral Agent represents and warrants that: (i) it has the full power and authority to execute this Release and (ii) it has not assigned, transferred, restricted or otherwise encumbered its rights under the Security Agreement. Collateral Agent acknowledges that this Release may be filed along with any other necessary documentation with the USPTO or any other governmental office to evidence the release granted herein at the sole expense of Grantor. The Collateral Agent authorizes Grantor to record this Release with the USPTO and other applicable registry at the sole expense of Grantor and agrees to provide Grantor with any information and additional authorization necessary to effect the release of the security interest in the Released Collateral.

[Signature page follows.]

IN WITNESS WHEREOF, Collateral Agent has executed this Release of Security Interests in Trademarks as of the date first set forth above.

**COLLATERAL AGENT:**

**GOLDMAN SACHS SPECIALTY LENDING  
GROUP, L.P.**

By: \_\_\_\_\_

Name: *David Miller*

Title: *Senior Vice President*







*J.P.*


[Signature Page to Release of Security Interests in Trademarks]

**TRADEMARK  
REEL: 006648 FRAME: 0328**

Exhibit A

Trademark Registrations/Applications

TRADEMARK	SERIAL NUMBER / REGISTRATION NUMBER	FILING DATE / REGISTRATION DATE
	Reg. No. 4420640	10/22/13
CUTISPHARMA	Reg. No. 4473417	1/28/14
	Reg. No. 5244475	7/18/17
	Reg. No. 3275609	8/7/07
FIRST	Reg. No. 2636155	10/15/02
	Reg. No. 4678283	1/27/15
	Reg. No. 4416915	10/15/13
	Reg. No. 4416916	10/15/13

	Reg. No. 4615796	10/7/14
SMART PRODUCTS FOR SMART PEOPLE	Reg. No. 3410259	4/8/08
TRANSFORMING COMPOUNDING THROUGH INNOVATION	Reg. No. 5055386	10/4/16
TRANSFORMING MEDICINE THROUGH INNOVATION	Reg. No. 5360667	12/19/17
FIRVANQ	Application No. 1859135	9/25/17
FIRVANQ	Application No. 017232752	9/21/17
	Application No. 1771137	3/7/16
	International Reg. No. 1296679	3/7/16 <sup>1</sup>
TRANSFORMING MEDICINE THROUGH INNOVATION	Application No. 1800763	9/16/16
TRANSFORMING MEDICINE THROUGH INNOVATION	Reg. No. 015819171	3/22/17
RXM THERAPEUTICS	Reg. No. 19256574	4/14/17
VANFYRST	Application No. 1859133	9/25/17

<sup>1</sup> India issued a Notice of Provisional Refusal of Protection on March 30, 2017, and the time for responding or requesting reconsideration has expired.

VANFYRST	Application No. 01732802	9/21/17
----------	--------------------------	---------